This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information
Nintedanib* plus docetaxel in routine clinical practice: VARGADO ‒ a German prospective non-interventional study reflecting routine treatment conditions in an evolving NSCLC treatment landscape
Grohé C, Zander I, Lüdtke-Heckenkamp K, Blau W, Krüger S, Franke C, Müller-Huesmann H, Brückl W, Basara N, Ukena D, Lang S, Atz J, Kaiser R
*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.
© 2018 Boehringer Ingelheim International GmbH. All rights reserved.
Last updated: October 2018